Total Payments
$456,898
2024 Payments
$51,506
Companies
42
Transactions
1,294
Medicare Patients
3,097
Medicare Billing
$3.4M
Payment Breakdown by Category
Other$366,791 (80.3%)
Travel$39,064 (8.5%)
Food & Beverage$31,903 (7.0%)
Consulting$18,990 (4.2%)
Education$149.86 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $364,291 | 169 | 79.7% |
| Travel and Lodging | $39,064 | 184 | 8.5% |
| Food and Beverage | $31,903 | 930 | 7.0% |
| Consulting Fee | $18,990 | 6 | 4.2% |
| Honoraria | $2,500 | 1 | 0.5% |
| Education | $149.86 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $168,786 | 366 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $166,502 | 233 | $0 (2024) |
| Shire North American Group Inc | $32,504 | 58 | $0 (2019) |
| Genentech USA, Inc. | $15,740 | 32 | $0 (2024) |
| PFIZER INC. | $15,612 | 78 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $14,632 | 33 | $0 (2018) |
| Optinose US, Inc. | $13,716 | 51 | $0 (2024) |
| GlaxoSmithKline, LLC. | $12,167 | 114 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,564 | 54 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $3,920 | 13 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $51,506 | 161 | AstraZeneca Pharmaceuticals LP ($44,339) |
| 2023 | $34,338 | 172 | AstraZeneca Pharmaceuticals LP ($22,843) |
| 2022 | $36,992 | 160 | AstraZeneca Pharmaceuticals LP ($24,569) |
| 2021 | $31,241 | 134 | AstraZeneca Pharmaceuticals LP ($14,550) |
| 2020 | $26,644 | 93 | GlaxoSmithKline, LLC. ($9,724) |
| 2019 | $90,131 | 193 | Novartis Pharmaceuticals Corporation ($57,418) |
| 2018 | $95,107 | 191 | Novartis Pharmaceuticals Corporation ($50,944) |
| 2017 | $90,939 | 190 | Novartis Pharmaceuticals Corporation ($48,172) |
All Payment Transactions
1,294 individual payment records from CMS Open Payments — Page 1 of 52
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Respiratory | ||||||
| 12/17/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.31 | General |
| Category: Immunology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: BIOLOGIC | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $123.24 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $71.48 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Respiratory | ||||||
| 11/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $787.67 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $113.40 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $29.48 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $120.28 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $63.15 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 823 | 34,046 | $4.9M | $1.3M |
| 2022 | 15 | 765 | 28,656 | $3.8M | $1.0M |
| 2021 | 17 | 794 | 23,306 | $2.5M | $703,759 |
| 2020 | 15 | 715 | 12,214 | $1.2M | $356,127 |
Total Patients
3,097
Total Services
98,222
Medicare Billing
$3.4M
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 38 | 26,415 | $3.0M | $795,362 | 26.2% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 16 | 2,670 | $1.3M | $352,522 | 26.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 60 | 1,144 | $299,728 | $67,193 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 196 | 319 | $62,205 | $31,293 | 50.3% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 56 | 1,430 | $35,750 | $17,783 | 49.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 94 | 171 | $25,725 | $11,936 | 46.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 66 | 66 | $18,150 | $8,405 | 46.3% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 69 | 678 | $20,340 | $6,371 | 31.3% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 26 | 628 | $9,420 | $2,138 | 22.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 30 | 30 | $2,100 | $2,058 | 98.0% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 26 | 241 | $4,820 | $1,946 | 40.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 62 | 71 | $7,100 | $1,534 | 21.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 35 | 35 | $1,225 | $1,122 | 91.6% |
| 95076 | Test for allergy using ingested items, initial 2 hours | Office | 2023 | 12 | 12 | $4,200 | $1,106 | 26.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $2,700 | $1,024 | 37.9% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 12 | 110 | $1,650 | $751.15 | 45.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 13 | 14 | $2,100 | $389.28 | 18.5% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 32 | 22,230 | $2.5M | $662,445 | 26.4% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 13 | 1,860 | $935,580 | $245,457 | 26.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 52 | 584 | $161,843 | $36,118 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 188 | 305 | $59,475 | $31,597 | 53.1% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 61 | 1,500 | $37,500 | $18,894 | 50.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 95 | 159 | $23,850 | $11,367 | 47.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 62 | 62 | $17,050 | $8,284 | 48.6% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 79 | 617 | $18,510 | $5,783 | 31.2% |
About Dr. Anthony Rooklin, MD
Dr. Anthony Rooklin, MD is a Allergy & Immunology healthcare provider based in Glen Mills, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013008333.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Rooklin, MD has received a total of $456,898 in payments from pharmaceutical and medical device companies, with $51,506 received in 2024. These payments were reported across 1,294 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($364,291).
As a Medicare-enrolled provider, Rooklin has provided services to 3,097 Medicare beneficiaries, totaling 98,222 services with total Medicare billing of $3.4M. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Glen Mills, PA
- Active Since 09/28/2006
- Last Updated 03/02/2023
- Taxonomy Code 207K00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013008333
Products in Payments
- XOLAIR (Biological) $164,489
- FASENRA (Biological) $74,250
- FASENRA (Drug) $53,725
- AIRSUPRA (Drug) $31,395
- CUVITRU (Biological) $25,416
- Xolair (Biological) $15,817
- CIBINQO (Drug) $14,651
- Xhance (Drug) $13,716
- TRELEGY ELLIPTA (Drug) $10,349
- CINRYZE (Drug) $9,078
- UTIBRON (Drug) $5,472
- HYQVIA (Biological) $4,071
- CINQAIR (Drug) $3,866
- BEVESPI AEROSPHERE (Drug) $3,695
- LONHALA MAGNAIR (Drug) $2,958
- DUPIXENT (Biological) $1,882
- SYMBICORT (Drug) $1,628
- NUCALA (Biological) $649.08
- TEZSPIRE (Biological) $533.62
- TAKHZYRO (Biological) $394.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.